METHODS: Using the biodegradable material poly(lactic-co-glycolic acid) and fibrin, a high porosity external sheath carrying bosentan with a stratified internal spiral structure was made by grouping mould extraction and low-temperature deposition techniques. Bosentan, a dual endothelin A and B receptor antagonist, was carried in the new designed external sheath, and could be slowly released. Rabbits underwent carotid bypass with ipsilateral jugular vein without external sheath (control, Group C), with external sheath (Group S) or with external sheath carrying bosentan (Group S + B).
INTRODUCTION
The saphenous vein is one of the main vessel conduits to revascularize the myocardium. The major drawback of using the saphenous vein as a conduit is its low patency rate. There are several intrinsic and extrinsic causes that lead to early, short-term or longterm saphenous vein graft failure. Early failure occurs within 0-30 days, and is generally due to technical failures, such as kinking of the graft and anastomoses. Short-term [30 days to 2-year postcoronary artery bypass grafting (CABG)] failures are ascribed to the development of intimal hyperplasia. The long-term saphenous vein graft failure (more than 2-year post-CABG) is marked by increased intimal hyperplasia and development of atherosclerotic lesions [1] . However, effective treatments for saphenous vein graft failure have not been confirmed yet. Subsequent revascularization interventions, such as redo CABG or stent insertion, are indicated by clinical symptoms and signs associated with vein graft failure, and the surgery is likely to be more difficult with a poorer clinical outcome [2] . Therefore, a novel therapy to improve the late patency of vein grafts needs to be developed.
A large body of experimental works has been directed at attenuating the development of intimal hyperplasia in vein grafts. External stents or sheaths of vein grafts have been reported to lead to expansive remodelling or an increase in the lumen area. Biodegradable material seems to be a much more appropriate material for making external stents or sheaths [3] . The external drug delivering system placed on the adventitial surface of the vascular graft is another therapy with potency for inhibition of vein graft failure. Several drugs, such as rapamycin, p38 mitogenactivated protein kinase inhibitor, cilostazol and C-type natriuretic peptide, have been reported to prevent the restenosis of arterialized vein grafts [4] [5] [6] . These results lead to a hypothesis that additional therapeutic effects against restenosis of vein grafts can be induced by combination of external sheaths with external drug delivering.
Endothelin receptor antagonist has been shown to reduce neointimal development following coronary angioplasty in an experimental model [7] , and prevent in-stent restenosis of coronary artery [8] . However, it is still not known whether endothelin receptor antagonist can contribute to the prevention of restenosis of vein grafts. In the current study, a high porosity external sheath of the biodegradable material poly(lactic-co-glycolic acid) (PLGA) and fibrin with a stratified internal spiral structure was made by grouping mould extraction and low-temperature deposition techniques. Bosentan, a dual endothelin A and B receptor antagonist, was carried in the new designed external sheath, and could be slowly released. We investigated whether the new designed external sheath with slow-release bosentan could inhibit the restenosis of vein grafts in a rabbit model.
MATERIALS AND METHODS

Animal care
Japanese white rabbits weighing 2.0-2.5 kg were used in the study. The animal protocol was approved by the Ethics Review Committee for Animal Experimentation of China Medical University (Shenyang, China), and was in accordance with the National Institutes of Health Guide for the Use and Care of Laboratory Animals (National Institutes of Health, Bethesda, MD, USA).
Measurement of the mechanical properties and degradation of poly(lactic-co-glycolic acid) patch Using polyurethane (PU) patches (5 cm × 2 cm × 2 mm) as control, the elasticity modulus and elongation at break of PLGA patches (5 cm × 2 cm × 2 mm) were measured in vitro as described previously [9] . In brief, the patch was mounted within a tension device, where it was subjected to a specific strain between 0 and that sufficient to cause a rupture. The external sheathes of PU or PLGA (25 mm) were compressed along the long axis. When the length was compressed to 50%, the sheath was released. The recovery of the length was used for the calculating rate of elastic recovery.
Degradation of PLGA patches was also investigated in vitro according to the method reported by Loh XJ et al. [10] . In brief, the PLGA patches or PLGA patches carrying bosentan were incubated in phosphate buffer solution ( pH 7.4) and the solution was changed every week. The patch was weighed weekly and the weight was expressed as a percent of the initial weight. The pH data of the solution were measured before it was changed.
Design of the external sheath
A high porosity external sheath with stratified internal spiral structure was made by grouping mould extraction and low temperature deposition techniques. The outer layer was made of the biodegradable material PLGA and the fibrin was coated inside. Five percent bosentan was mixed into PLGA and fibrin. As shown in Fig. 1 , the inner diameter was 4 mm and the thickness was 2 mm. The length was 25 mm. For the internal spiral structure, the thread pitch was 3 mm and the depth of the thread was 1 mm. At each end of the sheath, there was a 5-mm free edge without spiral structure.
Surgical procedure
General anaesthesia was achieved in each rabbit upon the administration of 10 mg/kg of ketamine hydrochloride intravenously and 3 mg/kg of xylazine intramuscularly. The no-touch technique was used to harvest a 30-mm segment of the right external jugular vein through a midline vertical neck incision, and all branches were carefully ligated. The jugular vein was passed through the external sheath. At both ends of the vein graft, a 2-mm free edge without external sheath was used for anastomosis. After systemic heparinization (200 U/kg), the ipsilateral common carotid artery was clamped distally and proximally, and a vein graft was anastomosed in an end-to-side fashion into the divided artery with continuous 8-0 polypropylene sutures. Pulsatile blood flow to the venous graft was confirmed. The carotid artery was ligated externally with 4-0 silk suture. Oral administration of aspirin (50 mg/day) was given during the first 7 days after operation.
Experimental protocol
Rabbits were assigned into three groups randomly (n = 10 for each group). Group C (control) underwent carotid artery bypass with naked vein grafts; Group S (external sheath) underwent carotid artery bypass with vein grafts supported by the external sheath without bosentan. Group S + B (external sheath + bosentan) underwent carotid artery bypass with vein grafts supported by the external sheath carrying slow-release bosentan. All animals were sacrificed 9 weeks after the operation.
Vascular ultrasound examination
The blood flow velocity and the diameter of vein grafts were measured through vascular ultrasound examination with a 10-l probe just after the interposition, 1 week and 8 weeks after the interposition. The change rate of peak velocity (r) was determined as 
Histological examination
For histological study, rabbits were sacrificed 9 weeks after the operation. Paraffin-embedded sections (4 μm) of vein grafts were stained with haematoxylin and eosin (HE). To display collagen and proteoglycan, the sections were also stained with Masson or Alcian Blue, respectively. The long and short diameters of the transverse section of vein grafts, the thickness of the intima and media the area of the intima/media and the lumen were measured with the magnification of ×40. The ratio of long diameter to short diameter was used to evaluate the shape of the transverse section of the vein graft. The ratio equal to 1 is defined to be a round shape. The ratio of the area of intima-media/area of lumen was used to evaluate the lumen of the vein graft.
Statistical analysis
Parametric values are reported as mean ± standard deviation, and were analysed by t-test or one-way analysis of variance followed by the Student-Newman-Keuls post hoc test. Statistical significance was defined as P-value <0.05.
RESULTS
Mechanical properties of poly(lactic-co-glycolic acid) patch
Compared with PU patches, the elasticity modulus of PLGA patches was significantly higher while the elongation at break and rate of elastic recovery of PLGA patches were significantly lower (P < 0.01, respectively, Fig. 2 ), indicating that PLGA patches were more difficult to make an elastic deformation under a stress.
Degradation of poly(lactic-co-glycolic acid) patches
As shown in Fig. 3 , weights of PLGA patches or PLGA patches carrying bosentan decreased continuously and the patches almost degraded completely after incubation with phosphate buffer saline (PBS) for 8 weeks. No significant difference of the rate of weight loss was detected between PLGA patches and PLGA patches carrying bosentan (P > 0.05, Fig. 3 ). The pH data of the PBS incubation at the end of every week before it was changed are shown in Fig. 3 and no marked difference was found between the two groups (P > 0.05).
In vivo, no residual of the sheath was found to be located on vein grafts when vein grafts were harvested 9 weeks after interposition, indicating external sheaths with bosentan or without bosentan degraded completely.
Vascular ultrasound examination
Ultrasonic flow images of vein grafts are shown in Fig. 4A . The velocities of vein grafts of all the three groups were decreased 1 week after the operation as evidenced by the increase of r values and no significant difference was detected (P > 0.05, Fig. 4B ). Eight weeks after the operation, the velocity of vein grafts in Group S + B recovered almost to the level just after the operation, while the velocity of vein grafts in Group C decreased significantly (P < 0.01, 4B ). The external sheath without bosentan also inhibited the decrease of blood velocity of vein grafts (P < 0.01 vs Group C; P < 0.05 vs Group S + B, Fig 4B) .
Similar enlargement of the diameter was detected in vein grafts of all the three groups 1 week after the operation (P > 0.05, Fig. 4C) . However, the diameter of vein grafts of the three groups was found to be decreased 8 weeks after the operation. Significant difference of the r 0 value was found among the three groups. The r 0 value of the Group C was much higher than those of the Group S and Group S + B (P < 0.01, respectively, Fig. 4C ). Compared with the Group S, the r 0 value of the Group S + B was still much lower (P < 0.05, Fig. 4C ). 
Histological examination
Sections stained with HE are shown in Fig. 5A . The wall of the intact jugular vein was thin and the intima, media and adventitia could be detected distinctly. The intima and media thickened significantly in the arterialized vein without any intervention and the lumen of the graft was narrow and irregular. However, intact endothelium could be found in vein grafts with external sheath or external sheath carrying bosentan and the intima and the media thickened symmetrically.
The ratios of long diameter to short diameter were 198 ± 23%, 107 ± 7% and 111 ± 5% in Group C, the Group S and the Group S + B, respectively (P < 0.01 vs Group C, respectively, Fig. 5B ). These data indicated that the transverse section of the vein graft without external sheath deviated from a circular shape and the local shear force for wall of the vessel was asymmetrical.
The ratio of the area of intima-media/area of lumen was used to evaluate the lumen of the vein graft. The increase of the ration reflects the decrease of the patency of the graft. The ratio of the area of intima-media/area of lumen is shown in Fig. 5B . Such a ratio of Group C was significantly higher than that of the other two groups (P < 0.01 vs the Group S + B; P < 0.05 vs the Group S). Such a ratio was still lower in Group S + B when compared with that of the Group S (P < 0.05).
For the ratio of thickness of intima/thickness of media, the Group S + B was significantly lower than that of the Group C (P < 0.01) or Group S (P < 0.05). Compared with the Group C, such a ratio of the Group S was also decreased significantly (P < 0.05).
Collagen was specifically displayed by Masson staining. In the wall of the vein graft of Group C, little collagen arranged in disorder was detected. While, much more collagen well arranged in the media was found in the wall of the vein graft of the Group S or the Group S + B. The arrangement of collagen in the graft in the Group S + B was more closely to that in an artery (Fig. 6) . Similarly, much more proteoglycan stained by Alcian Blue was detected in the vein graft of the Group S + B and the arrangement was also similar to that of an artery (Fig. 7) .
DISCUSSION
The salient findings of the current study can be summarized as follows: (i) the biodegradable external sheath significantly prevented the intimal hyperplasia of vein grafts; (ii) by combining slow-release bosentan with the novel designed external sheath, the beneficial effects against intimal hyperplasia were further improved.
Beneficial effects of external stents or sheaths around vein grafts have been described in collective experimental studies [11] [12] [13] . Even in a clinical trial, external reinforcement with a polytetrafluoroethene prosthesis allowed the use of autogenous greater saphenous veins with varicose dilatation, and enabled the construction of all autogenous bypasses with promising graft patency and limb salvage [14] . Collectively, two kinds of external stents or sheaths, stents of loose-fitting mesh or sheaths that were tightly woven, have been investigated. Unsupported grafts were found to have more sub-endothelial proliferation and therefore a narrower vessel lumen than in the grafts with loose-fitting mesh and the thickness of the intima and media was in inverse proportion to the number of vasa vasorum found in the graft adventitia. The adventitia of the loosely stented vein grafts was more heavily vascularized than that of the veins supported by the tightly woven sheaths. Additionally, as a result of the porosity of the loose mesh, the vasa vasorum were able to penetrate through the stent right into the vein graft wall [3] . In the current study, the novel designed external sheaths prevented the neointimal hyperplasia, and increased the lumen when compared with the grafts without external sheaths. As the external sheaths were made of a high porosity material, and were designed as a stratified internal spiral structure, the novel external sheaths possessed the peculiarity of the loose-fitting mesh, and might induce the growth of vasa vasorum.
It is still controversial as to whether the external sheath or stent should be placed tightly or loosely around the vein graft. As the structure of wall of the vein is different from that of the artery, the lumen of the arterialized vein is prone to expansion. Therefore, the rationale behind using a restrictive stent was to prevent overdistension of the vein graft and to adapt the larger vein lumen to the diameter of the host artery [15] . In a non-human primate study, moderate constriction was found to be sufficient for mitigating diffuse intimal hyperplasia and endothelial detachment [16] . Distention and subsequent damage of the vein graft were inhibited by use of a constrictive mesh even in patients undergone CABG [15] . In an in vitro closed-loop model, reproducible vessel wall changes were observed in all human vein graft specimens studied. Tight perivenous support was demonstrated to reduce the turbulent flow, and prevent the injuries to wall of the saphenous vein [17] . However, the restrictive stent or sheath may interrupt the development of new vasa vasorum, and contribute to ischaemic damage to the graft wall [18, 19] . Oversized stents have been shown to give equally profound suppression of intimal thickening as that induced by mildly restrictive or non-restrictive stents [19] . In the current study, the inner diameter of the external sheath was very close to the diameter of the jugular vein, which could be mildly restrictive to the vein graft. The special internal spiral structure of the external sheath prevents the entire surface of the vein graft from fitting too tightly with the external sheath and the disadvantages of the restrictive stent might thus be avoided. Therefore, our novel designed external sheath may possess the specialties both of the tight stent and the loose stent, and may be much more beneficial.
As a foreign material, the long-term support of vein grafts with external stents may elicit untoward effects including infection, foreign body/inflammatory reactions and mechanical complications, which may induce persistent fibrosis with contraction and seroma formation, leading to narrowing of the vein graft [20] . It has been proposed that stenting the vein with a biodegradable material would initially support the graft against over-distension, and confers the benefits of external stenting on the vein graft. While the graft arterializes and adapts to new pressures and flows, the stent is degraded over time [3] . A polyglactin biodegradable external stent has been shown to prevent medial and intimal thickening, and promote marked neo-vasa vasorum formation in porcine saphenous vein grafts in both the short term and long term [21] . In trials examining biodegradable stents, it was noted that the graft media was heavily infiltrated with macrophages. Inflammatory cell-mediated angiogenesis was associated with the biodegradation of the stent material [3] . PLGA is highly biocompatible, and remains today as one of the few 'real-world' biodegradable synthetic biomaterials used in US Food and Drug Administration-approved parenteral long-acting-release products [22] . As far as we know, this is the first study that PLGA was used for an external sheath. Vein grafts supported by the novel biodegradable external sheath had already adapted to the arterial pressures and flows, and shown some specialties of an artery when the external sheath degraded completely. The current external sheath possesses a nice deformability/pliability that can be attributed to the elasticity of PLGA and the special internal spiral structure. The area of the internal spiral is thinner than other area, and will degrade earlier ( 4 weeks). Then, the external sheath will be deformed as a spring, and possesses a much greater degree of deformability/pliability. The external sheath can be changed easily according the circuitous route of the vain grafts.
The potent vasoconstrictor and mitogen endothelin-1 has been implicated in the pathogenesis of restenosis and vascular hypertrophy. Non-selective endothelin A/B receptor antagonist has been shown to block proliferation of rat vascular smooth muscle cells after balloon angioplasty [23] . Dual endothelin A/B receptor antagonist or selective endothelin B receptor antagonist showed significant reduction of intimal hyperplasia in an organ culture of human saphenous vein [24] . Oral treatment with bosentan reduced neointimal development following coronary angioplasty in an experiment of pigs [7] . As PLGA is an ideal polymer for formulation of long-term control drug release, bosentan was slowly released from our novel designed external sheath during its degradation. Bosentan was confirmed to have beneficial effects on inhibition of the intimal hyperplasia of the vein graft, as evidenced by the better lumen and better matrix remodelling in vein grafts supported by the external sheath carrying slow-release bosentan than in the grafts with external sheath without bosentan.
The primary limitation of the current study was that the mechanisms of beneficial effects against restenosis of vein grafts induced by the biodegradable external sheath carrying slowrelease bosentan were not investigated in detail. As the material and structure of our external sheath is special, additional mechanisms may be involved to induce its beneficial effects against intimal hyperplasia of arterialized vein grafts. Although the beneficial effects of the novel external sheath were obtained from a 9-week experiment, further study is necessary to get the longterm results. In rabbits, the external jugular vein bypass model is often used for experimental study, but the external jugular vein is quite unlike the saphenous vein that has valves. In the current study, the vein grafts were just kept in the condition of a normal arterial blood pressure of rabbits. The arterial blood pressure of rabbits was not controlled. The pressure to inflate the vein grafts was not measured.
In summary, the current experiment demonstrates that our novel designed degradable vascular external sheath with slowrelease bosentan can inhibit hyperplasia of intima and media, and improve the shape of experimental vein grafts. By using a biodegradable material and the special internal spiral structure, our novel external sheath possesses unique superiority. As a vehicle for slow-release drugs, therapeutic drugs can be carried to the novel external sheath and the beneficial effects can be further improved. We believe that our novel designed external sheath possesses a potential clinical value in the prevention of the restenosis of the vein grafts in coronary artery bypass grafting.
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